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LETTERS TO THE EDITORThere is no sex equality in carotid disease
In his commentary in the Journal of Vascular Surgery Abstract
section on the article by Henriksson et al,1 which concluded that to
all intents and purposes carotid endarterectomy (CEA) was not
cost-effective in women with asymptomatic carotid disease, Dr
Greg Moneta2 observed that although the data were interesting, it
seemed “politically untenable to deny women, and not men,
prophylactic CEA for high grade asymptomatic stenosis.”
At first sight, this seems a not unreasonable observation, but it
does require the reader to assume that women gain equivalent
clinical benefit (in terms of long term stroke prevention) to men. In
fact, this is not the case. In the original Asymptomatic Carotid
Atherosclerosis Study (ACAS) publication,3 the authors conceded
that CEA did not confer significant benefit in women, with an
absolute risk reduction in ipsilateral stroke of 1.7% at 5 years. Even
when all strokes and deaths occurring in the first 30 days were later
excluded,4 there was still no significant benefit observed in women.
ACST subsequently claimed that CEA conferred significant benefit
in women,5 but this was only the case if the operative risk was
excluded (ie, the 5-year benefits were modelled on a zero percent
procedural risk). Once the procedural risk was included, all signif-
icant benefit in women ceased.6
When the ACAS and Asymptomatic Carotid Surgery Trial
(ACST) data were combined, the Cochrane Collaboration7 per-
formed a subgroup analysis in 1644 women and again noted that
CEA did not significantly reduce the 5-year risk of stroke compared
with best medical therapy (odds ratio, 0.96; 95% confidence interval,
0.63-1.45). The lower magnitude of benefit observed in women is
almost certainly due to a combination of there being a slightly higher
procedural risk compared with men (a consistent finding across all of
the symptomatic and asymptomatic randomized trials and also in a
systematic review of the published literature)8 combined with a lower
late natural history risk of stroke compared with men.
The article by Henriksson et al is undoubtedly a provocative
way of demonstrating the reduced clinical benefit conferred by
CEA in women, and Greg Moneta’s observation will be typical of
many who are intuitively reluctant to treat men and women
differently. More important, until the guideline makers address
this issue, surgeons will remain reluctant to advise against offering
CEA to women because of a very real fear of uncritical medicolegal
censure. This, if nothing else, is another compelling reason for
urging the principle investigators of trials comparing CEA with
carotid stenting in asymptomatic patients to include a medical arm
in the randomization process. Continuing to ignore this important
clinical issue is also neither professionally nor politically tenable.
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Regarding “Carotid artery stenting has increased
rates of postprocedure stroke, death, and resource
utilization than does carotid endarterectomy in the
United States, 2005”
In December 2008, McPhee et al warned about the dangers of
carotid artery stenting (CAS) in increasing risks of perioperative
mortality (1.1% vs 0.57%, P  .04) and stroke (1.8% vs 1.1%, P 
.05; odds ratio [OR] 1.7; 95% confidence interval [CI] 1.2-2.3)
compared with carotid endarterectomy (CEA).1 The warnings,
based on large U.S. coding datasets and published in The Journal
of Vascular Surgery, immediately raised great resonance condemn-
ing CAS. Are these alerts completely justified? At this point we do
not know, since the numbers and the data are not as powerful as
the conclusive words to prove increased mortality and stroke risks.
According to multivariate analysis in the McPhee paper, the
only strong predictors of perioperative mortality were renal
failure (OR 2.7; 95% CI 1.6-4.6, P  .0004) and congestive
heart failure (CHF) (OR 2.8; 95% CI 1.7-4.5, P .0001), these
being the same two baseline factors significantly more frequent
in the CAS vs CEA group (3.9% vs 3%, P  .02 and 11.4% vs
6.8%, P  .0001, for renal failure and CHF in CAS and CEA,
respectively). The higher mortality in CAS patients could be due
to the procedure itself or more realistically, the high fatality rate
was biased by baseline unbalance and a higher proportion of
patients with high fatality risk factors at baseline.
Even if CAS finally passes in the future, the procedure will never
be for all practitioners. It is required that CAS be performed exclu-
sively in centers with specific dedicated experience and adequate
training. Large beds and teaching hospitals may be enough to provide
high medical and surgical standards of care but may not be enough to
ensure safe proficiency with new procedures as CAS. In the McPhee et
al dataset, CAS population was about 10% of the overall population
(90% being CEAs), suggesting that CAS centers were not actively
working and were without large carotid experience. It would be
interesting if the Authors could provide the number of CAS proce-
dures per center (or better, the number of CAS per operators, if data
are available) to provide data on experience and include this in a
multivariate analysis on outcome. With a track record of less than 50
CAS, it is not recommended to perform CAS.2,3
Are CAS and CEA populations, as detected by the coding
datasets, truly representative of the U.S. reality? It is quite unusual
that 90% of CEA were performed in asymptomatic patients and
almost half of the population was female (in other series, females
were about 30% and asymptomatics about 60%).4 These are two
subgroups (asymptomatic and female) of patients for whom treat-
ment of carotid stenosis has been proven to be of lesser benefit,
particularly in U.S. carotid trials (Asymptomatic Carotid Athero-
